CDH1 and carcinoma: Besides these tumors, where E‐cadherin status supports diagnosis, its aberrant expression has also been associated with diverse clinicopathological features in various carcinomas such as colon, lung, ovary, esophagus, prostate, or cervix, among others (reviewed in Steinestel et al., 2014).